Treatment Patterns and Survival in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Literature Review of 35 Real-World Observational Studies.

Treatment landscapes have changed dramatically in prostate cancer in the past decade. Therapies like androgen receptor pathways inhibitors (ARPIs), which were initially approved for mCRPC are now approved in the earlier disease spectrum, including biochemical recurrence (BCR), non-metastatic castration-resistant prostate cancer (nmCRPC), and hormone-sensitive metastatic prostate cancer (mHSPC).